Heterogeneity of tumour mutational burden in metastatic NSCLC demonstrated by endobronchial ultrasound sampling

INTRODUCTION: Tumour mutational burden (TMB) is an important emerging biomarker for immune checkpoint inhibitors (ICI). The stability of TMB values across distinct EBUS tumour regions is not well defined in advanced lung cancer patients. METHODS: This study included a whole-genome sequencing cohort...

Descripción completa

Detalles Bibliográficos
Autores principales: Leong, Tracy L., Aloe, Christian, Aujla, Savreet, Wang, Hao, Gayevskiy, Velimir, Asselin-Labat, Marie-Liesse, Gray, Lesley-Ann, Steinfort, Daniel, Bozinovski, Steven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10042177/
https://www.ncbi.nlm.nih.gov/pubmed/36994206
http://dx.doi.org/10.3389/fonc.2023.1150349

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10042177/
https://www.ncbi.nlm.nih.gov/pubmed/36994206
http://dx.doi.org/10.3389/fonc.2023.1150349

Ejemplares similares